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 L1 (also known as L1CAM or CD171) is a trans-
membrane glycoprotein belonging to the Ig 
superfamily of cell adhesion molecules (CAMs 
[Ig-CAMs]), which mediate calcium-indepen-
dent cell – cell adhesion. The L1 gene is located 
on the X chromosome in human, mouse, and 
rat. The extracellular portion of the protein 
contains six Ig-like domains and fi ve fi bronec-
tin type III repeats, followed by a transmem-
brane region and a cytoplasmic domain ( 1 ). L1 
has long been characterized as a cell recognition 
molecule within the nervous system, where it 
is involved in neurite fasciculation, synapto-
genesis, axonal growth and path fi nding, and 
cell migration. In humans, mutations in the 
L1 gene cause abnormal brain development, 
which is characterized by mental retardation 
and defects in the central nervous system ( 2 ). 
These neurological alterations were, at least in 
part, recapitulated in mice where the L1 gene 
was disrupted ( 3, 4 ). 
 L1-dependent cell – cell adhesion is mediated 
by the homophilic binding between L1 molecules 
located on adjacent cells. However, L1 also 
engages in heterophilic interactions with diff erent 
molecular partners, including other Ig-CAMs, 
integrins, and growth factor receptors. These 
interactions, together with the association of its 
cytoplasmic tail with a broad spectrum of intra-
cellular partners, endow L1 with the signal-
transducing properties that underlie its neural 
activities ( 1 ). 
 Besides the nervous system, L1 expression 
has been reported in various normal tissues, rang-
ing from some epithelia to certain lineages of 
the hematopoietic system, as well as in several 
tumor types. In these nonneuronal tissues, 
however, L1 function is still poorly understood. 
Within the hematopoietic system, L1 has been 
detected in cells of myelomonocytic and lym-
phoid origin such as lymphocytes and DCs ( 5 ). 
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 The adhesion molecule L1, which is extensively characterized in the nervous system, is also 
expressed in dendritic cells (DCs), but its function there has remained elusive. To address 
this issue, we ablated L1 expression in DCs of conditional knockout mice. L1-defi cient DCs 
were impaired in adhesion to and transmigration through monolayers of either lymphatic or 
blood vessel endothelial cells, implicating L1 in transendothelial migration of DCs. In agree-
ment with these fi ndings, L1 was expressed in cutaneous DCs that migrated to draining 
lymph nodes, and its ablation reduced DC traffi cking in vivo. Within the skin, L1 was found 
in Langerhans cells but not in dermal DCs, and L1 defi ciency impaired Langerhans cell 
migration. Under infl ammatory conditions, L1 also became expressed in vascular endothe-
lium and enhanced transmigration of DCs, likely through L1 homophilic interactions. Our 
results implicate L1 in the regulation of DC traffi cking and shed light on novel mechanisms 
underlying transendothelial migration of DCs. These observations might offer novel 
therapeutic perspectives for the treatment of certain immunological disorders. 
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recombination was expected to be more effi  cient in L1-f loxed 
males. Hence, only Tie2-Cre – positive males carrying the 
f loxed  L1cam allele (referred to as  Tie2-Cre;L1 f loxed mice) 
were used throughout the study. 
 The correct function of the Tie2-Cre transgene was veri-
fi ed by Cre immunoblotting analysis on undiff erentiated 
bone marrow precursors (Fig. S2 C, top). These precursors 
showed no expression of L1 at this stage (Fig. S2 C, bottom). 
The ablation of L1 in Tie2 + hematopoietic progenitors did 
not cause major defects in mouse hematopoiesis, as blood cell 
counts for erythrocytes and the diff erent leukocyte populations 
gave very similar values for both  L1 f loxed and  Tie2-Cre;L1 f loxed 
littermates (unpublished data). In addition, the loss of L1 did 
not aff ect the cellular composition of mouse lymph nodes 
(Fig. S2 E), including the relative amounts of DC subpopula-
tions (Fig. S2 F). Finally, although Tie2-Cre mice have been 
used to target genes expressed in ECs ( 8 ) and L1 expression 
in the vessels has been reported under pathological condi-
tions ( 10, 11 ), no gross vascular defects were noted in  Tie2-
Cre;L1 f loxed mice. 
 To investigate the role of L1 in DCs, bone marrow pre-
cursors were cultured in the presence of GM-CSF, a classical 
inducer of DC diff erentiation. This treatment yielded a nearly 
pure population of CD11c + cells ( Fig. 1 B ), confi rming their 
diff erentiation into DCs. Bone marrow – derived DCs isolated 
from  L1 f loxed mice exhibited high levels of L1, which is de-
tectable by both FACS and immunoblotting analysis ( Fig. 
1 B , top; and Fig. S2 D). In contrast, L1 was not detected in 
DCs derived from the bone marrow of  Tie2-Cre;L1 f loxed mice 
( Fig. 1 B , bottom; and Fig. S2 D), indicating that Tie2 pro-
moter-driven expression of Cre recombinase results in the 
ablation of L1 in this cell type. 
 The role of L1 in DC adhesion to endothelium 
and transendothelial migration 
 To study the role of L1 in DC biology, we fi rst asked whether 
this adhesion molecule is involved in the maturation of DCs. 
Bone marrow – derived DCs were stimulated with LPS and 
then the expression of classical activation markers was analyzed. 
The loss of L1 did not aff ect LPS-induced up-regulation of 
CD86 ( Fig. S3 A ), CD80, and MHC class II (not depicted), 
indicating that DC maturation is not infl uenced by L1. In 
addition, the level of L1 was not aff ected by LPS stimulation 
of DCs (Fig. S3 B). 
 Next, we investigated whether L1 is involved in the 
interaction of DCs with the lymphatic vessel endothelium, a 
key process in DC traffi  cking to lymphoid organs ( 12 ). To 
this goal, DCs derived from  L1 f loxed or  Tie2-Cre;L1 f loxed bone 
marrows were subjected to adhesion assays on monolayers of 
lymphatic ECs (LECs). Two mouse LEC lines were used, 
MELCs ( 13 ) and SV-LECs ( 14 ). In both cases,  Tie2-Cre;L1 f loxed 
DCs exhibited a lower adhesion capacity to lymphatic endo-
thelium as compared with DCs from control  L1 f loxed mice 
( Fig. 2, A and B ). Furthermore, L1-positive DCs spread 
and extended cellular protrusions upon adhesion to LECs, 
whereas  Tie2-Cre;L1 f loxed DCs retained a round morphology 
DCs play a key role in the activation of specifi c immunity, 
and their traffi  cking to secondary lymphoid organs is crucial 
for this function. Indeed, upon microbial contact and stimu-
lation by infl ammatory cytokines DCs take up antigens and 
migrate from peripheral tissues, via the aff erent lymphatics, into 
the T cell area of the draining lymph node where they present 
the antigens to T lymphocytes, thus triggering the immune 
response. The migration of DCs into and out of tissues 
depends on a cascade of discrete events including the induction 
of chemokines, the activation of chemokine receptors, and 
the regulation of adhesion molecules. In particular, transendo-
thelial migration is of paramount importance during DC-
 induced immune response because DCs need to cross both 
the blood vessel wall, to move from the bloodstream to the 
peripheral tissue, and the lymphatic endothelium, to reach the 
lymph nodes via the lymphatic circulation ( 6 ). Based on these 
considerations and on the reported role of L1 in cellular 
 motility and in intercellular recognition, we investigated the 
involvement of L1 in DC function and, in particular, in the 
transmigration of DCs across the endothelium. 
 To this goal, we generated conditional knockout mice in 
which L1 expression was ablated in the hematopoietic pre-
cursors as well as in endothelial cells (ECs). L1-defi cient DCs 
derived from these mice were impaired in both adhesion to 
the endothelium and in transendothelial migration. More-
over, DC migration to aff erent lymph nodes upon contact 
sensitization was also defective in conditional L1 knockout 
mice, likely also involving endothelial L1. Thus, we have 
provided evidence that highlights the important role of L1 in 
DC traffi  cking, which may open novel therapeutic perspec-
tives for the treatment of immune disorders. 
 RESULTS 
 Generation of conditional L1 knockout mice 
and characterization of DCs 
 L1 has been detected in human DCs ( 5 ). To investigate whether 
mouse DCs also express L1, we collected lymph node cells 
from C57BL/6 mice and determined L1 expression in CD11c + 
cells. Approximately 55% of DCs were found to be positive 
for L1 ( Fig. 1 A ). The analysis of DC subpopulations showed 
L1 expression in 45% of CD4 + , 40% of CD8 + , and 40% of 
B220 + DCs, whereas 85% Langerhans cells were positive for 
L1 ( Fig. S1 A ). Similar results were obtained in DCs isolated 
from the spleen (Fig. S1 B). The widespread expression of L1 
in Langerhans cells was also confi rmed in the epidermis (see 
fourth paragraph). 
 To gain insight into the role of L1 in DC function, we 
fi rst undertook a genetic approach in mice. The tyrosine kinase 
receptor Tie2 is expressed in early precursors of hematopoi-
etic and ECs ( 7 ). Hence, transgenic mice expressing Cre re-
combinase under the control of the  Tie2 gene promoter ( 8 ) 
were intercrossed with  L1 f loxed mice carrying two f loxed 
alleles of the  L1cam gene ( 9 ). The genotype of the mice was 
determined by PCR on genomic DNA ( Fig. S2, A and B ). 
Because the  L1cam gene maps on chromosome X (and, there-
fore, only one copy is present in male genome), Cre-mediated 
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 We next asked whether the loss of L1 also aff ected the migra-
tion of DCs across a lymphatic endothelial barrier. Both basal-
to-apical and apical-to-basal directions were tested to mimic 
intra- and extravasation of DCs, respectively. By analogy to 
cell adhesion, the migration rate of L1-defi cient DCs through 
a lymphatic endothelial monolayer was markedly lower than 
that of control cells ( Fig. 3 A ). L1 was required for both apical-
to-basal and basal-to-apical DC transmigration ( Fig. 3 A , left 
and middle). Moreover, because transendothelial migration of 
DCs also occurs across the wall of blood vessels ( 12 ), we in-
cluded blood vascular ECs in our transmigration assays, using 
the mouse EC line 1G11 ( 15 ). As in the case of LECs, the loss 
of L1 resulted in the impairment of DC migration through 
1G11 monolayers ( Fig. 3 A , right), implicating L1 in the traf-
fi cking of DCs across both lymphatic and blood vessel walls. 
Very similar results were obtained when the transendothelial 
migration of either immature or mature DCs across lymphatic 
or blood vessel ECs was stimulated by the chemokines CCL3 
or CCL19, respectively ( Fig. S4 A ). Notably, L1 defi ciency by 
( Fig. 2 B , inset). The stronger adhesion of L1-expressing bone 
marrow – derived DCs was not the result of an L1-dependent 
regulation of   2 integrins because no diff erence in   2 expres-
sion was observed between  L1 floxed and  Tie2-Cre;L1 floxed DCs 
and the two cell populations adhered to purifi ed ICAM-2 
(a major   2 ligand) with similar effi  ciency (unpublished data). 
The role of L1 in the interaction of DCs with the lymphatic 
endothelium was also assessed using DCs freshly isolated from 
lymph nodes. In this case, L1 + and L1    DCs were separated 
by FACS sorting and labeled with diff erent dyes before adhe-
sion assays on SV-LEC monolayers. As shown in  Fig. 2 C , 
lymph node – derived L1 + DCs adhered twice more effi  ciently 
than L1    cells to the lymphatic endothelium, confi rming the 
results obtained with bone marrow – derived DCs. L1    DCs 
isolated from the lymph nodes of  Tie2-Cre;L1 f loxed mice 
showed an adhesion rate to lymphatic endothelium comparable 
to that of L1    DCs from  L1 f loxed mice (unpublished data). 
These results supported the notion that L1 is required for 
DC – LEC interaction. 
 Figure 1.  Ablation of L1 in DCs from  Tie2-Cre;L1 fl oxed mice. (A) CD11c-positive cells from the lymph nodes of C57BL/6 mice (left) were gated and 
analyzed for L1 expression (right). Background staining was determined with a control isotype-matched antibody (black line). The experiment was re-
peated with lymph nodes from fi ve individual mice with similar results, and the fi gure refers to one representative analysis of one mouse. (B) FACS analy-
sis of CD11c and L1 coexpression in bone marrow – derived DCs from  L1 fl oxed and  Tie2-Cre;L1 fl oxed mice. The experiment was repeated with similar results on 
four individual mice for each genotype, and the fi gure refers to one representative analysis. 
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confi rmed with DCs obtained from at least fi ve mice for each 
genotype. Moreover, each experiment was performed com-
paring DCs isolated from  L1 f loxed and  Tie2-Cre;L1 f loxed litter-
mates to rule out the eff ect of genetic variability. Nevertheless, 
to validate these observations in an isogenic model, DCs de-
rived from  L1 f loxed mice were transduced with the Tat-Cre 
fusion protein, which is known to promote the nuclear trans-
location of Cre recombinase ( 16 ). As a control, cells were 
treated either with buff er or with an inactive form of Tat-Cre 
itself did not aff ect the migratory ability of DCs, as neither the 
chemotactic migration toward the CCL3 or CCL19 chemo-
kines (Fig. S4 B) nor the motility of DCs within three-dimen-
sional collagen type I matrix (not depicted) were aff ected in 
 Tie2-Cre;L1 f loxed DCs. This argued against a cell autonomous 
eff ect of L1 on DC motility and further supported its specifi c 
involvement in DC – EC interactions. 
 The diff erence between L1-profi cient and defi cient DCs 
in adhesion to and migration through endothelial barriers was 
 Figure 2.  L1 regulates the adhesion of DCs to endothelium. (A and B) CFSE-labeled bone marrow – derived DCs from  L1 fl oxed and  Tie2-Cre;L1 fl oxed mice 
were seeded on TNF-  – stimulated MELC (A) or SV-LEC (B) monolayers and allowed to adhere for the indicated time lengths. After washing and fi xation, cell 
adhesion was measured as described in Materials and methods. Data represent the means  ± SD of a single representative experiment performed in tripli-
cate. The experiment was independently repeated fi ve times, each time using DCs from different mice. The insets in B show the morphology of DCs seeded 
on SV-LEC monolayers. Bar, 10  μ m. *, P  < 0.05; **, P  < 0.005 (relative to  L1 fl oxed DCs). (C) Mouse inguinal lymph node cells were enriched for CD11c + cells and 
then FACS sorted into CD11c + /L1 + and CD11c + /L1    DCs (top, postsorting cell populations), which were then labeled with CFSE (green) and PKH26 (red), re-
spectively, before adhesion assays on TNF-  – stimulated SV-LEC monolayers (bottom left, example of DC adhesion; bar, 30  μ m). Data in the bottom right 
represent the means  ± SD from three independent experiments, each performed with lymph nodes from three mice. *, P  < 0.05 (relative to L1-positive DCs). 
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in vivo. To address this issue, we performed a series of FITC 
skin painting assays, in which FITC was applied on the skin 
of  L1 f loxed or  Tie2-Cre;L1 f loxed mice, and then the uptake of 
FITC by cutaneous DCs and their traffi  cking to draining 
lymph nodes was determined by FACS analysis. As shown 
in  Fig. 3 B , the number of FITC + /CD11c + cells in the 
lymph nodes of  Tie2-Cre;L1 f loxed mice was markedly lower 
than in their  L1 f loxed littermates. More than 85% of FITC + /
CD11c + DCs detected in the lymph nodes of  L1 f loxed mice 
were positive for L1 ( Fig. 3 C ), confi rming that this mole-
cule is expressed in skin migratory DCs. Collectively, these 
results indicate that L1 is required for the traffi  cking of DCs 
in vivo. 
(unpublished data). The transduction of  L1 f loxed DCs with 
Tat-Cre resulted in the almost complete ablation of L1 ex-
pression ( Fig. S5 A ). This, in turn, caused a dramatic decrease 
in both apical-to-basal and basal-to-apical transendothelial 
migration of DCs (Fig. S5 B), thus confi rming that the loss of 
L1 impairs this process. Collectively, these observations point 
to L1 as an important player in the endothelial adhesion and 
transendothelial migration of DCs. 
 The role of L1 in DC traffi cking in vivo 
 Our in vitro data on the role of L1 in the interaction of 
DCs with the endothelium might refl ect an involvement of 
this adhesion molecule in the vascular trafficking of DCs 
 Figure 3.  L1 is required for DC transendothelial migration and traffi cking to lymph nodes. (A) For apical-to-basal transmigration assays, SV-LEC 
(left) or 1G11 cells (right) were seeded on the upper side of gelatin-coated Transwell fi lters and allowed to form dense monolayers. For basal-to-apical 
migration assays (middle), SV-LECs were cultured on the bottom side of the fi lters. ECs were pretreated with TNF-  before transmigration assays. CFSE-
labeled bone marrow – derived DCs from  L1 fl oxed and  Tie2-Cre;L1 fl oxed mice were added to the upper chamber of Transwell inserts. After 3 h, DC transmigra-
tion was measured as described in Materials and methods. Data represent the means  ± SD of representative experiments performed in triplicate with DCs 
from fi ve mice for each genotype. *, P  < 0.05; **, P  < 0.005 (relative to  L1 fl oxed DCs). (B) FITC skin painting was performed on the abdomen of  L1 fl oxed or 
 Tie2-Cre;L1 fl oxed mice. After 24 h, inguinal lymph nodes were excised and subjected to FACS analysis for FITC and CD11c. Data are expressed as the per-
centage of FITC-positive cells and represent the means  ± SD of a representative experiment (six mice per group) out of three performed. *, P  < 0.05 
(relative to relative to  L1 fl oxed mice). (C) FITC-positive cells in inguinal lymph nodes (left) were gated and analyzed for L1 and CD11c expression (right). 
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type that migrates to lymph nodes upon skin painting. This 
hypothesis was confi rmed by a FACS analysis on the lymph 
nodes of  L1 f loxed mice subjected to TRITC skin painting 
assays, which revealed that almost 100% of TRITC + /CD11c + 
cells are Langerhans cells and that   97% of TRITC + cells 
coexpress langerin and L1 ( Fig. 4 C , left). When the same 
analysis was performed in  Tie2-Cre;L1 f loxed mice, we observed 
a dramatic decrease (about fourfold) in TRITC + Langerhans 
cells in the lymph nodes ( Fig. 4 C , right), which correlated 
with the effi  ciency of Cre-mediated ablation of L1 (not de-
picted). This is exemplifi ed in  Fig. 4 C (right), where, of the 
residual TRITC + cells that migrated to the lymph nodes, the 
majority expressed L1. Previous studies using TRITC skin 
painting assays reported that, besides Langerhans cells, dermal 
DCs also migrate to the lymph nodes ( 18, 20 ), an event 
which was not observed under our experimental conditions. 
Although the reason for such a discrepancy remains unclear, 
it may depend on the diff erent genetic background of the 
mice used in those studies (129/SV;BALB/c) as compared 
with ours (C57BL/6). Our data further support the notion 
that L1 is critical for Langerhans cell traffi  cking. The reduc-
tion in Langerhans cell migration was not caused by a lower 
 The role of L1 in Langerhans cell traffi cking 
 To investigate whether the loss of L1 aff ects DC-dependent 
immune response, we focused on skin immunity and per-
formed contact hypersensitization assays. However, no dif-
ference was observed between  L1 f loxed and  Tie2-Cre;L1 f loxed 
mice ( Fig. 4 A ). Because skin immunity has been proposed to 
implicate dermal DCs rather than Langerhans cells ( 17, 18 ), 
we asked whether L1 expression is restricted to specifi c sub-
types of cutaneous DCs. The costaining of mouse and human 
skin tissues for L1, CD11c, and the Langerhans cell – specifi c 
marker Langerin revealed that L1 is specifi cally expressed in 
Langerhans cells but not in dermal DC ( Fig. 4 B and  Fig. S6 ). 
The staining of epidermal sheets confi rmed that L1 expres-
sion is a general feature of Langerhans cells ( Fig. S7 ). The ab-
sence of L1 in dermal DCs provided a possible explanation 
for the unaff ected contact hypersensitivity (CHS) in  Tie2-
Cre;L1 f loxed mice. Indeed, when fl uorescent latex beads were 
injected into mouse derma to track the migration of dermal 
DCs or of infi ltrating monocytes to draining lymph nodes 
( 19 ), we found no diff erence in DC migration in the pres-
ence or absence of L1 (Fig. S4 C). These observations pointed 
to L1-expressing Langerhans cells as the most prominent DC 
 Figure 4.  L1 is not required for CHS but is involved in Langerhans cell traffi cking. (A) CHS was determined in  L1 fl oxed or  Tie2-Cre;L1 fl oxed mice by 
ear-swelling assay at different time points (six mice per genotype), as described in Material and methods. Error bars show the SD among the six individual 
mice of the same genotype. (B) Skin tissue sections from C57BL/6 mice were subjected to immunofl uorescence triple staining for CD11c, Langerin, and L1, 
followed by confocal analysis. The images were taken from a single confocal plane. The dashed line indicates the boundary between epidermis (left) and 
dermis (right). Arrowheads indicate CD11c + /Langerin + Langerhans cells that express L1 and arrows indicate CD11c + /Langerin    dermal DCs that do not 
express L1. Asterisks indicate an L1-positive nerve that served as internal control. DAPI staining (right) was used to visualize nuclei. Bar, 10  μ m. (C)  L1 fl oxed 
(left) or  Tie2-Cre;L1 fl oxed (right) mice were subjected to TRITC skin painting, followed by excision of inguinal lymph nodes after 48 h and FACS analysis for 
CD11c, langerin, and L1 on TRITC + -gated cells. Four mice were analyzed individually for each genotype, giving similar results, and the fi gure refers to a 
representative analysis of one mouse per genotype. 
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 The role of L1 in the transendothelial migration 
of human DC 
 Given the diff erence between human and murine immune 
systems, we asked whether L1 is also involved in the transen-
dothelial migration of human DCs. To this goal, we used 
human monocyte-derived DCs (moDCs), which express 
moderate levels of L1 ( Fig. 5 A ; reference  5 ). The maturation 
of human moDCs was not accompanied by changes in L1 
levels (not depicted), confi rming our observations on mouse 
bone marrow – derived DCs (Fig. S3 B). To evaluate the role 
of L1 in transendothelial migration, CFSE-labeled moDCs 
were pretreated with CE7, a monoclonal antibody that has 
been previously shown to neutralize L1 function ( 21 ), and 
then allowed to cross a monolayer of TNF-  – activated human 
umbilical vein ECs (HUVECs). The inactivation of L1 in moDCs 
with CE7 resulted in a dramatic reduction of the transendo-
thelial migration as compared with moDCs treated with an 
irrelevant antibody ( Fig. 5 B ). Given the expression of L1 in 
activated ECs ( 10 ) as well as in TNF-  – treated HUVECs 
(see  Fig. 7 A ), we also assessed the contribution of vascular L1 
to DC transendothelial migration by pretreating HUVECs 
with CE7 before transmigration assays. The inactivation of 
endothelial L1 caused a reduction in the transmigratory acti-
vity of moDCs ( Fig. 5 B ). Finally, when L1 was neutralized 
in both DCs and HUVECs, no additive eff ect was observed 
as compared with the inactivation in the individual cell types 
( Fig. 5 B ). Notably, CE7 had no eff ect on chemokine-in-
duced migration of moDCs (not depicted), which is in line 
with the results on L1-defi cient mouse DCs (Fig. S4 B). 
Thus, L1 function is required for the traffi  cking of human 
DCs through an endothelial barrier. 
number of Langerhans cells in the skin of  Tie2-Cre;L1 f loxed 
mice because we found no diff erence in the distribution and 
density of Langerhans cells and dermal DCs between  L1 f loxed 
and  Tie2-Cre;L1 f loxed mice (unpublished data). Overall, these 
results indicate that in the skin Langerhans cells are the only 
DC type expressing L1 and are aff ected by L1 defi ciency in 
their ability to migrate in vivo. It is noteworthy, however, 
that the skin painting procedure induced L1 expression in 
skin vessels (unpublished data). Thus, vascular L1 could con-
tribute to Langerhans cell migration, accounting to some ex-
tent for the defect observed in  Tie2-Cre;L1 f loxed mice, where 
L1 is also ablated in the endothelium. 
 Figure 5.  L1 function is required for transendothelial migration 
of human DCs. (A) The expression of L1 in human moDCs was as-
sessed by FACS analysis. (B) CFSE-labeled moDCs were subjected to 
transmigration assays through HUVEC monolayers (see Materials and 
methods) for 2 h. moDCs, HUVECs, or both cell types were pretreated 
with 30  μ g/ml of anti-L1 CE7 monoclonal antibody or a control 
isotype-matched anti-hemagglutinin (HA) antibody before trans-
migration assays. Data represent the means  ± SD of a representative 
experiment performed in triplicate. The experiment was independently 
repeated three times. *, P  < 0.005 (relative to cells treated with anti-
HA antibody). 
 Figure 6.  L1 expression in pathological vessels. Tissue sections from 
human synovitis, ovarian, colon, or breast carcinoma were subjected to 
immunohistochemical staining for L1. Arrows indicate L1 staining asso-
ciated with the vessel wall, whereas the arrowhead in D indicates an 
L1-positive nerve that served as the internal control. The staining was 
performed on sections from at least four independent patients for each 
disease. Bars, 50  μ m. 
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tors, we treated ECs with infl ammatory cytokines, followed 
by the assay for L1 expression. Although LPS, IL-1  , and IL-3 
had no eff ect on L1 levels in HUVEC and 1G11 cells (not 
depicted), a marked up-regulation was induced by TNF-  , 
as observed both by FACS ( Fig. 7, A and B ) and by quantita-
tive RT-PCR ( Fig. 7 C ), the latter implying a regulation at 
the messenger RNA level. To verify whether TNF-  in-
duced the expression of vascular L1 also in vivo, the cytokine 
was injected subcutaneously into mice, followed by costain-
ing of skin sections for PECAM-1 and L1. Although no L1 
was detected in the vessels of control mice ( Fig. 7, D – F ), 
high levels of L1 were found in PECAM-1 – positive endo-
thelium of TNF-  – treated mice ( Fig. 7, G – I ), confi rming this 
infl ammatory cytokine as a strong inducer of L1 expression in 
the vasculature. Costaining for PECAM-1 and the lymphatic 
vessel-specifi c marker LYVE-1 ( 23 ) revealed that TNF-  –
 induced expression of L1 occurred in both blood and lymphatic 
 L1 homophilic binding in DC – endothelium interaction 
 The results on the transmigration of moDCs through HU-
VEC monolayers appeared to implicate the homophilic inter-
action of L1 on DC surface with L1 expressed on ECs. To test 
this hypothesis, we fi rst determined whether ECs express L1. 
Immunofl uorescence and immunoblotting experiments re-
vealed the presence of L1 in several primary cell populations 
isolated from the endothelium of lymphatic and blood vessels 
derived from diff erent human and murine organs, as well as 
in established EC lines ( Fig. S8, A and B ). We also investigated 
the endothelial expression of L1 in vivo by immunohisto-
chemistry. L1 was absent from normal quiescent vasculature 
(not depicted), but it was detected on the vessels associated to 
pathological conditions such as neoplastic or infl ammatory 
diseases ( Fig. 6 ), confi rming and extending previous observa-
tions ( 10, 22 ). Because this suggested that the expression of 
L1 is regulated by tumor- or infl ammatory cell – derived fac-
 Figure 7.  TNF-  induces L1 expression in endothelium. (A) HUVEC or 1G11 cells were starved of serum and endothelial growth factors and then treated 
with 20 ng/ml TNF-  for 3 h, followed by FACS analysis for L1 expression. (B) HUVEC were treated with 20 ng/ml TNF-  for the indicated time lengths, fol-
lowed by FACS analysis for L1 expression. The data refer to the percentage of L1-positive cells in a representative experiment. Each experiment was repeated 
three times with similar results. (C) HUVECs were treated with 20 ng/ml TNF-  for the indicated time lengths before isolation of RNA and quantitative RT-PCR 
analysis for L1 expression. Data represent the means  ± SEM of three experiments performed. *, P  < 0.05 (relative to untreated cells). (D – I) C57BL/6 mice (three 
mice per group) were subjected to subcutaneous injection of 100  μ l of either vehicle (D – F) or 40 ng/ml TNF-  (G-I) and sacrifi ced after 16 h. Skin fragments 
from the injection sites were fi xed and costained for PECAM-1 (red) and L1 (green) before confocal analysis. Insets show a blood vessel cross section with the 
ECs positive for both PECAM-1 and L1. The arrow in F indicates an L1-positive nerve that served as an internal control. Bars, 40  μ m. 
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heterophilic binding partners of L1 involved in DC – EC in-
teractions remain elusive, members of the integrin family are 
suitable candidates. Indeed, the cross talk between integrins 
and Ig-like CAMs, such as members of the ICAM and JAM 
families, is a key step during leukocyte transmigration ( 28 ). In 
support of this hypothesis, not only has L1 been reported to 
interact with integrins in other experimental systems ( 10, 29, 30 ) 
but L1 homophilic binding upon cell-cell adhesion has been 
shown to promote integrin recruitment and activation ( 31 ). 
In this context, L1-mediated stimulation of the integrin   v  3 
favors the interaction of melanoma with ECs, a process that 
precedes melanoma cell intravasation ( 32 ). The infl amma-
tion-associated induction of L1 expression in ECs is intrigu-
ing. Despite the fact that L1-positive vessels in infl ammatory 
lesions have been reported ( 10 ) and confi rmed by our immuno-
histochemical analysis, L1 has not been investigated as part of 
the adhesion molecule repertoire that is induced by infl am-
matory stimuli in the endothelium ( 28 ). Our study provides the 
fi rst evidence that L1 is indeed a transcriptional target of an 
infl ammatory cytokine, such as TNF-  , in ECs. In vivo, L1 
is not expressed on ECs under steady-state conditions but it 
is up-regulated after TNF-  treatment, supporting the no-
tion that this event is part of the infl ammatory reaction rather 
than a phenomenon restricted to cultured ECs. Based on our 
results on human ECs where the neutralization of L1 causes 
a reduction in DC transmigration, it is conceivable that 
 infl ammation-induced vascular L1 serves the function of 
enhancing the transendothelial traffi  cking of DCs. In this 
context, the Tie2-Cre transgene is also expressed in the en-
dothelium ( 8 ), implying that the induction of vascular L1 
under infl ammatory conditions would not occur in  Tie2-
Cre;L1 f loxed mice. The possibility that endothelial L1 contrib-
utes to DC traffi  cking presents an attractive hypothesis that 
deserves further investigation. Moreover, although our data 
suggest that L1 on DCs establishes heterophilic interactions 
with EC surface molecules (see beginning of paragraph), it 
remains to be established whether endothelial L1 also binds 
to diff erent molecules on the surface of DCs. This would im-
plicate a complex network of L1-mediated interactions in 
DC transendothelial migration during infl ammation. 
 In spite of L1 ’ s role in DC transendothelial migration in 
vitro and traffi  cking in vivo, contact hypersensitization was 
not aff ected in mice with L1-defi cient DCs. This might be 
accounted for by the residual fraction of DCs that migrated 
to the draining lymph nodes in  Tie2-Cre;L1 f loxed mice, which 
would have been suffi  cient to induce specifi c immunity. 
 Another explanation (not mutually exclusive with the previous 
one) relies on the fact that contact hypersensitization assays 
refl ect the induction of skin immunity, which is mediated by 
Langerhans cells and dermal DCs. Recent studies have spe-
cifi cally implicated dermal DCs in contact hypersensitization 
( 18 ), whereas Langerhans cells would not be involved in this 
process ( 17 ). Collectively with our observation that in mouse 
skin L1 is expressed in Langerhans cells but not in dermal 
DCs, this likely accounts for the normal contact hypersen-
sitization response of  Tie2-Cre;L1 f loxed mice. Future studies 
endothelium (Fig. S8 C). These fi ndings provided the rationale 
for testing whether L1 homophilic interactions accounted 
for the adhesion of DCs to the endothelium. Indeed, L1-ex-
pressing DCs, both from murine bone marrow and from hu-
man monocytes, adhered to gelatin supplemented with the 
extracellular portion of L1 much more effi  ciently than to L1-
free gelatin ( Fig. S9 A ). In contrast, L1-defi cient DCs failed 
to adhere to L1-containing substrates (Fig. S9 A). In an at-
tempt to mimic the infl ammation-associated induction of 
endothelial L1 and to recapitulate L1 homophilic binding 
during DC – endothelium interaction, 1G11 ECs were trans-
duced with L1 complementary DNA (cDNA) or with an 
empty vector (Fig. S9 B) and then used for transendothelial 
migration assays with  L1 f loxed or  Tie2-Cre;L1 f loxed DCs. Nota-
bly, control  L1 f loxed DCs exhibited a signifi cantly higher rate 
of transmigration across L1-expressing 1G11 monolayers 
than mock-transduced cells. In contrast, the forced expres-
sion of L1 in 1G11 cells had no eff ect on the transendothelial 
migration of  Tie2-Cre;L1 f loxed DCs (Fig. S9 C). Collectively, 
these fi ndings support the notion that the interaction be-
tween DCs and ECs implicates the homophilic binding of L1 
molecules expressed on the two cell types. 
 DISCUSSION 
 The contribution of L1 to various developmental processes in 
the nervous system has long been known. Recent studies have 
also implicated L1 in the aggressiveness of diff erent tumor 
types of nonneural origin such as colon cancer ( 24 ), melanoma 
( 25 ), and ovarian carcinoma ( 21, 26 ). However, the functional 
role of L1 in normal tissues outside the nervous system has 
 remained elusive. With regard to DCs, previous work has 
shown the expression of L1 in this cell type ( 5 ) and its contri-
bution to DC-dependent activation of T cells ( 27 ). In the 
present study, we addressed the role of L1 in DCs in greater 
detail by combining a genetic approach in mice with anti-
body-mediated neutralization in human DCs. Our results 
highlighted a novel function of L1 in promoting DC traffi  ck-
ing both in vitro and in vivo. In particular, L1 is involved in 
the adhesion of DCs to the endothelium and in their transmi-
gration through endothelial barriers. Interestingly, L1 medi-
ates both apical-to-basal and basal-to-apical transendothelial 
migration of DCs, suggesting an involvement in both extra- 
and intravasation, respectively. However, the L1-dependent 
migration of DCs was not a universal characteristic of skin 
DCs, and only L1-defi cient Langerhans cells were aff ected in 
their migratory properties in vivo. The functional signifi cance 
of this property remains to be elucidated. 
 L1-expressing DCs were able to cross an L1-negative en-
dothelium (Fig. S9 C), likely implicating heterophilic inter-
actions with diff erent partners on EC surface. However, the 
forced expression of L1 in ECs results in a marked enhance-
ment of DC transmigration (Fig. S9 C), which is consistent 
with the hypothesis that, during infl ammation, the induction 
of L1 expression in vessels (e.g., triggered by TNF-  ) poten-
tiates the transendothelial traffi  cking of DCs. Although the 
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These studies strengthen the rationale for assessing the inhibi-
tion of L1 as a strategy to repress DC traffi  cking in certain 
 immunological disorders. 
 MATERIALS AND METHODS 
 Mice 
 L1 floxed mice ( 9 ) were provided by M. Schachner and F. Morellini (University 
of Hamburg, Hamburg, Germany).  Tie2-Cre transgenic mice ( 8 ) were pro-
vided by E. Dejana (Milan, Italy). All mouse strains were backcrossed into the 
C57BL/6 background for eight or more generations. To obtain  Tie2-
Cre;L1 floxed mice,  L1 floxed females were crossed with Tie2-Cre males. Genomic 
DNA of the off spring was isolated from tail biopsies and the genotype was de-
termined by PCR ( supplemental Materials and methods ). All experiments 
were performed in accordance with the guidelines established in the Principles 
of Laboratory Animal Care (directive 86/609/EEC) and approved by the 
Italian Ministry of Health. 
 Antibodies 
 The following antibodies were used: hamster anti – mouse CD11c (clone HL3; 
BD); rat anti – mouse PECAM-1 (clone MEC13.3; BD); rat anti-Langerin 
(clone 929F3; Dendritics); rabbit anti – human L1 ectodomain (from M. 
Schachner, Hamburg, Germany) and rabbit anti – human L1 cytoplasmic tail 
pcyt-L1 ( from V. Lemmon, Miami, FL; reference  41 ); mouse anti – human L1 
(clone CE7; from K. Blaser, Davos, Switzerland; reference  42 ); and rat anti-L1 
(clones I4.2 and S10.33) generated against mouse L1 (but cross reacting with 
human L1; unpublished data) and characterized in our laboratory. 
 Cells 
 DCs.  Bone marrow – derived immature DCs were generated from single cell 
suspensions of marrow from femurs of 8 – 10-wk-old  L1 floxed or  Tie2-Cre;L1 floxed 
male mice. After 10 – 11 d of culture in GM-CSF – containing DC medium 
( 43, 44 ), the homogeneity of DCs was evaluated by FACS analysis with 
anti-CD11c (BD). No diff erences were observed between  L1 floxed or  Tie2-
Cre;L1 floxed bone marrow precursors in the proliferation rate or in the yield of 
CD11c-expressing DCs during GM-CSF – induced diff erentiation (unpub-
lished data). 
 Human moDCs were obtained from healthy volunteers as described pre-
viously ( 45 ). After 5 – 7 d of culture, cells were analyzed for DC markers and 
used for functional assays. 
 ECs.  The mouse blood vessel EC line 1G11, isolated from the lung, was pro-
vided by A. Vecchi (Milan, Italy) and cultured as previously described ( 15 ). 
The mouse LEC lines MELC ( 46 ) and SV-LEC ( 14 ) were provided by A. 
Vecchi (Milan, Italy) and J.S. Alexander (Shreveport, LA), respectively, and 
were cultured as previously described. Primary LECs from human prostate 
were isolated and cultured as previously described ( 47 ) and used between pas-
sages 3 and 6. HUVECs (PromoCell) were cultured in MCDB 131 medium 
(Invitrogen) supplemented with 2 mM l- glutamine, 20% FBS, 50  μ g/ml hep-
arin, and 50  μ g/ml EC growth supplement (Sigma-Aldrich). 1G11 cells, 
MELCs, SV-LECs, and HUVECs were seeded on 0.1 – 1% gelatin. Prostate 
LECs were cultured on plates coated with 10  μ g/ml fi bronectin (Sigma-
 Aldrich). Where specifi ed, ECs were treated with 20 ng/ml TNF-  (PeproT-
ech) for the indicated time points. 
 Immunohistochemistry 
 Immunohistochemistry on formalin-fi xed paraffi  n-embedded tissue sec-
tions was performed as described previously ( 26 ) using the polyclonal 
antibody pcyt-L1. Staining of sections was visualized with the ABC horse-
radish peroxidase kit (Vector Laboratories) and DAB peroxidase substrate 
(Sigma-Aldrich). For morphological analysis, tissues were counterstained 
with hematoxylin. 
 FACS 
 FACS analysis was performed on bone marrow – derived DCs, lymph node –
 derived cells, and ECs. In brief, cells were resuspended in RPMI medium 
should address the impact of L1 defi ciency in diff erent types 
of immune response that involve DCs in compartments other 
than the skin because the role of L1 in T cell activation has 
also been reported ( 27 ). 
 Our observation that L1 is found in specifi c subpopulations 
of DCs (e.g., Langerhans cells, bone marrow DCs, and moDCs 
but not dermal DCs or 45% of lymph node DCs) raises the 
hypothesis that the microenvironment is involved in the mod-
ulation of L1 expression in DCs in a tissue-specifi c manner. 
Along this line, we have previously reported that intestinal epi-
thelium plays a pivotal role in determining the phenotype of 
DCs ( 33 ). Hence, the regulation of L1 expression might be 
part of the  “ education ” of DCs by the local environment, 
which would enable DCs to carry out specialized functions 
that are required to deal with tissue-associated challenges. 
 Although the biological signifi cance of L1 expression on 
cancer-associated vasculature remains elusive, it is tempting 
to speculate that endothelial L1 in tumors triggers the traffi  ck-
ing of DCs in the absence of an overt infl ammation, resulting 
in the migration to lymph nodes of immature nonimmuno-
genic DCs ( 19 ). These cells could present tumor antigenic 
peptides in a tolerogenic fashion, thus contributing to tumor 
immunoevasion. 
 The impairment of DC traffi  cking upon loss of L1 might 
have important clinical implications. Other mouse models 
have revealed a role of L1 in the immune system, although 
not directly involving DCs. In L1-defi cient mice, the archi-
tecture of the white pulp border in the spleen was disrupted 
( 34 ), and L1 was implicated in the tissue remodelling of lymph 
nodes that occurs during the immune response ( 35 ). With 
regard to L1 function in humans, mutations in the L1 gene 
cause various neurological disorders that are grouped under 
the name L1 syndrome ( 2 ). This phenotype is largely recapit-
ulated in L1 knockout mice ( 4, 36 – 38 ). Although patients 
carrying L1 mutations are thoroughly examined for brain de-
velopment and functions, no information is available on their 
immune system. Our fi ndings raise the possibility that L1 syn-
drome is associated with a defective DC traffi  cking and pro-
vide the rationale for investigating the impact of L1 mutations 
on the patients ’ immune response. Besides the possible benefi t 
for the clinical management of L1 syndrome patients, such an 
approach might also contribute to assign the DC-regulatory 
function of L1 to specifi c domains and/or residues of the pro-
tein. Indeed, numerous syndrome-associated L1 mutations 
have been described, which are distributed across all domains 
( 2 ). Hence, the analysis of DC function in patients carrying 
diff erent L1 mutations would help to determine the relative 
contribution of individual L1 domains to DC traffi  cking. 
 Our study also points to L1 as a potential therapeutic tar-
get to modulate DC function, a notion which is supported by 
the blockade of transendothelial migration of human DCs 
upon inactivation of L1. In this context, the design of L1-tar-
geting strategies in vivo would benefi t both from preclinical 
studies where L1-neutralizing antibodies showed therapeutic 
effi  cacy in tumor-bearing mice ( 21, 39 ) and from the use of 
L1 antibodies for imaging purposes in cancer patients ( 40 ). 
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 Skin painting assay 
 Mice were painted on the shaved abdomen with 0.2 ml of either 0.5% tetra-
methylrhodamine-5-(and-6)-isothiocyanate (5(6) (TRITC; Invitrogen) or 
0.5% FITC (Sigma-Aldrich) in a 1:1 acetone/dibutylphthalate (vol/vol) mix-
ture. Inguinal lymph nodes were excised from treated mice after 24 or 48 h 
and disaggregated as described in the supplemental Materials and methods. 
Cell suspensions from FITC-painted mice were costained with PE-conju-
gated anti – mouse CD11c (BD) and Alexa Fluor 647 – conjugated anti – mouse 
L1 clone S10.33 followed by FACS analysis. Cell suspensions from TRITC-
painted mice, after staining with APC-conjugated anti – mouse CD11c or 
with Alexa Fluor 647 – conjugated anti – mouse L1 clone S10.33, were fi xed 
and permeabilized, followed by costaining with Alexa Fluor 488 – conjugated 
monoclonal antibody 929F3 anti-langerin (Dendritics), which recognizes the 
intracellular conformation of the protein ( 51 ), before FACS analysis. 
 CHS assays 
 CHS was induced and determined as previously described ( 52 ). In brief, 
the hapten 4-ethoxymethylene-2-phenyl-2-oxazoline-5-one (Oxazolone 
[OXA]; Sigma-Aldrich) was freshly prepared before CHS assays. For sensiti-
zation, mice were painted once (day 0) on the shaved abdominal skin with 
100  μ l of 3% OXA in 4:1 acetone/olive oil (vol/vol) solution. 5 d later (day 
+5), mice were challenged by the application of 10  μ l OXA (1%) on each 
side of the right ear, whereas the left ear received the vehicle alone. CHS 
 response was determined by measuring the thickness of the antigen-painted ear 
compared with that of the vehicle-treated contralateral ear by a micrometer 
(Mitutoyo) at 24 – 96 h after challenge. The results were expressed as percent-
age of thickness increase calculated over vehicle-treated contralateral ear. 
 Staining of mouse endothelium 
 100  μ l of 40 ng/ml of mouse TNF-  or the same volume of PBS were in-
jected subcutaneously in the inferior abdominal region of 6-wk-old C57BL/6 
mice. 16 h after the injection, mice were sacrifi ced and the skin around the 
area of injection was removed, embedded in Tissue-Tek OCT (Sakura), and 
snap frozen in liquid nitrogen. 5- μ m frozen sections were obtained using a 
cryostat (CM 199; Leica) and air dried overnight. Sections were fi xed in cold 
methanol and subjected to immunofl uorescence staining using rat anti –
 PECAM-1 followed by Cy3-conjugated secondary antibody (Jackson Immuno-
Research Laboratories). Tissue was fi xed again, blocked with excess rat IgG, 
and then incubated with Alexa Fluor 488 – conjugated rat anti – mouse L1 
(clone S10.33). The tissue was then mounted onto microscope slides and 
images were obtained as described for cell immunofl uorescence. 
 DC staining in mouse skin 
 Methanol-fi xed frozen sections of C57BL/6 mouse skin were stained over-
night at 4 ° C with rat anti – mouse Langerin and hamster anti – mouse CD11c. 
The day after, sections were incubated with an Alexa Fluor 647 – conjugated 
goat anti – rat antibody (Invitrogen) and with a Cy3-conjugated goat anti –
 hamster antibody (Jackson ImmunoResearch Laboratories), followed by an-
other fi xation step in cold methanol. After an additional blocking step with 
rat IgG, sections were then incubated with Alexa Fluor 488 – conjugated rat 
anti-L1 antibody (clone S10.33) for 2 h at room temperature. Stained tissues 
were then analyzed by confocal microscopy (TCS-SP2-AOBS; Leica). 
 Online supplemental material 
 The supplemental Materials and methods describes the experimental proce-
dures used for the experiments illustrated in supplemental fi gures. Fig. S1 
shows the phenotypic analysis of L1-expressing DCs in mouse lymph nodes 
and spleen. Fig. S2 illustrates the characterization of  L1 floxed and  Tie2-
Cre;L1 floxed mice. Fig. S3 shows the maturation of DCs in response to LPS. 
Fig. S4 shows the migratory response of DCs to chemokines and to the in-
jection of FITC-labeled beads. Fig. S5 shows the reduced transendothelial 
migration of  L1 floxed DCs treated with Tat-Cre. Fig. S6 and Fig. S7 show the 
specifi c expression of L1 in Langerhans cells. Fig. S8 shows the expression of 
containing 1% normal mouse serum and then incubated with the specifi c 
fl uorophore-conjugated antibody. Cells were then analyzed by a FACSCali-
bur apparatus (BD). For FACS analysis on HUVEC, cells were incubated 
with rabbit anti – human L1 ectodomain antibody followed by Alexa Fluor 
488 – conjugated anti – rabbit antibody (Invitrogen). 
 Quantitative RT-PCR analysis 
 Total RNA was isolated by extraction with TRIzol (Invitrogen), and 1  μ g 
was reverse transcribed with random hexamers (High Capacity cDNA Ar-
chive kit; Applied Biosystems) according to the manufacturer ’ s instruc-
tions. 5 ng cDNA was amplifi ed in triplicate in a reaction volume of 15  μ l 
using TaqMan Gene Expression Assay ID Hs00240928_m1 (Applied Bio-
systems), which is designed for the detection of human L1 cDNA, and an 
ABI/Prism 7900 HT thermocycler (Applied Biosystems). Preparations of 
RNA template without reverse transcription were used as negative con-
trols. For each sample, the expression level of L1 was normalized to 
GAPDH using the comparative threshold cycle method as previously de-
scribed ( 48 ). 
 Adhesion assays 
 LECs (SV-LEC and MELC) were grown as monolayers on gelatin-coated 
96-well plates and stimulated with 20 ng/ml TNF-  for 16 h before DC ad-
hesion assays. DCs were labeled with 5  μ M CFSE, and 10 5 labeled cells per 
well were added and incubated at 37 ° C. At the indicated time points, cells 
were washed and fl uorescence was measured using a fl uorimeter (Multilabel 
Counter; Wallac 1420; Perkin Elmer). After subtraction of background cell 
binding (assessed using BSA-coated wells), cell adhesion was calculated as 
follows: adhesion = BF/TF  × C/A, where BF is bound fl uorescence, TF 
is total initial fl uorescence, C is the number of cells per well (10 5 ), and A is 
the well area (32 mm 2 ). In some experiments, DCs were purifi ed from cell 
suspensions from mouse lymph nodes using CD11c MACS MicroBeads 
(Miltenyi Biotec) according to the manufacturer ’ s instructions and then 
FACS sorted into L1-positive and L1-negative DCs using Alexa Fluor 647 –
 conjugated anti-L1 antibody S10.33 and PE-conjugated anti-CD11c (BD). 
The two DC populations were then labeled with CFSE and PKH26, respec-
tively, before adhesion assays on SV-LEC monolayers. Cell adhesion was 
determined by counting green and red cells. 
 Where specifi ed, CFSE-labeled DCs were seeded on 96-well plates pre-
coated with 60  μ g/ml of the extracellular portion of mouse (mL1-Fc) or hu-
man (hL1-ECD) L1 in 1% gelatin. The construct for mL1-Fc ( 49 ) was a gift 
from M. Schachner, and the expression vector encoding histine-tagged hL1-
ECD was provided by S. Silletti (University of California, San Diego, La 
Jolla, CA). Both recombinant proteins were expressed in 293 cells and puri-
fi ed from the conditioned medium by protein G (for mL1-Fc) or nickel 
 affi  nity chromatography (for hL1-ECD). 
 Transendothelial migration assays 
 MELCs, SV-LECs, HUVECs, and 1G11 cells were grown as monolayers on 
gelatin- or fi bronectin-coated Transwell inserts with a 5- μ m pore (Costar; 
Corning) as described previously ( 50 ). ECs were stimulated with 20 ng/ml 
TNF-  for 16 h before DC transmigration assays. CFSE-labeled DCs 
(10 5 cells) were seeded onto the endothelial monolayers and incubated for 
diff erent time lengths. In some experiments, MELCs and SV-LECs were 
grown on the lower side of the fi lter to determine basal-to-apical transmigration 
of DCs. Transwell inserts were thoroughly washed with PBS, fi xed in PFA, 
and mounted onto microscope slides (Menzel-Gl ä ser). Images of CFSE-
 labeled DCs were obtained with a microscope (Biosystems BX-71; Olympus). 
The number of CFSE-labeled DCs that crossed the fi lter was determined by 
counting the fl uorescent cells. 
 The migration of CFSE-labeled human moDCs across HUVEC 
barriers was determined after preincubating DCs, HUVECs, or both with 
30  μ g/ml CE7, a monoclonal antibody with L1 blocking function proper-
ties. As a control, an isotype-matched anti-HA antibody was used at the 
same concentration. Cell transmigration was determined as described in the 
previous paragraph. 
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